Dimerix confirms successful data collection for interim analysis

Dimerix Limited (ASX: $DXB) has successfully collected data from the first 72 patients randomized in the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS). The company expects to report the outcome of the Part 1 analysis on or before 15th March 2024, following the planned IDMC meeting.

Dr Nina Webster's Commentary on Milestone Achievement

We are absolutely delighted to have reached this important milestone. I would like to thank all of our patients for agreeing to be part of this trial to date, as well as our CRO and our amazing Dimerix team. We are now only a matter of days away from our Part 1 analysis outcome and, on the presumption of success, are continuing to prepare for Part 2 of the Phase 3 study. Success in Part 1 would signal that DMX-200 is performing better than placebo in reducing proteinuria, an important marker of kidney disease progression, in a larger cohort of patients than our prior Phase 2 study and validates our strategy and our prioritization of this potentially valuable program.

Summary of Dimerix's Progress and Outlook

Dimerix Limited (ASX: $DXB) has achieved a significant milestone by successfully collecting data for the first interim analysis in the ACTION3 Phase 3 trial of DMX-200 for FSGS. The company anticipates reporting the Part 1 analysis outcome by 15th March 2024, pending the IDMC meeting. Dr Nina Webster, CEO & Managing Director of Dimerix, expressed delight and gratitude towards the patients, CRO, and the Dimerix team for their contributions. The successful outcome of Part 1 would validate the efficacy of DMX-200 in reducing proteinuria, marking a crucial advancement in the treatment of FSGS. With the trial enrolling approximately 286 patients and a second interim analysis planned, Dimerix remains committed to addressing the unmet medical needs in FSGS. The company's focus on developing innovative therapies underscores its dedication to improving the lives of patients with inflammatory diseases, including kidney and respiratory diseases.